Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Introduction: Primary myelofibrosis (MF) is a rare hematologic disease belonging to the group of Philadelphia-negative chronic myeloproliferative neoplasms. Identification of the Janus Kinase (JAK) gene mutations inaugurated a new era in the targeted therapy of myeloproliferative diseases. Ruxolitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Casares, María Teresa, Hernández-Boluda, Juan Carlos, Jiménez-Velasco, Antonio, Martínez-López, Joaquin, Ferrario, María Giovanna, Gozalbo, Irmina, Gostkorzewicz, Joana, Subirá, Rudi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090464/
https://www.ncbi.nlm.nih.gov/pubmed/35620778
http://dx.doi.org/10.36469/9808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090464/
https://www.ncbi.nlm.nih.gov/pubmed/35620778
http://dx.doi.org/10.36469/9808

Ejemplares similares